Andriulli et al evaluated the response of patients with viral hepatitis C (HCV) to therapy with peginterferon and ribavirin. A patient who clears the virus early is the best candidate to obtain viral eradication. The authors are from multiple institutions in Italy.
Patient selection: HCV type 1 treated with dual therapy (peginterferon and ribavirin)
Parameters:
(1) F4 hepatic fibrosis
(2) serum GGT
(3) baseline HCV RNA in 10^3 IU/mL
(4) IL28B genotype (CC, CT or TT)
Parameter
Finding
Points
F4 hepatic fibrosis
absent
0
present
-0.63
serum GGT
normal
0
abnormal
-0.47
HCV RNA
-0.71 * LOG10(HCV RNA)
IL28B
CC
0
CT or TT
-1.37
where:
• In Table 2 the beta-coefficient for IL28B is 1.37, but LN(0.49) is -1.37 per page 820.
• The handling of viral load is ambiguous (either absolute load or 10^3/mL). The absolute load is used in the implementation.
value of X =
= 4.21 + SUM(points for all of the parameters)
probability of rapid viral response =
= 1/(1+EXP((-1) * X))
To read more or access our algorithms and calculators, please log in or register.
